{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:16:54Z","timestamp":1792815414133,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pure erythroid leukemia (PEL), also known as acute erythroid leukemia (AEL), is recognized as a distinct morphologic entity by both the 2016 and 2022 World Health Organization (WHO) classification system. By contrast, the 2022 International Consensus Classification (ICC) includes PEL under a broader category of \u201cacute myeloid leukemia with mutated <jats:italic>TP53<\/jats:italic>\u201d. We identified 41 Mayo Clinic cases of PEL (mean age 66 years, range 27\u201386; 71% males) and provide a comprehensive account of bone marrow morphology, immunophenotype, cytogenetic and mutation profiles. PEL was primary in 14 cases, therapy-related in 14, secondary in 12, and undetermined in one. All cases expressed biallelic <jats:italic>TP53<\/jats:italic> alterations, including <jats:italic>TP53<\/jats:italic> deletion\/single <jats:italic>TP53<\/jats:italic> mutation (68%), two <jats:italic>TP53<\/jats:italic> mutations (29%) or two <jats:italic>TP53<\/jats:italic> deletions (3%); additional mutations were infrequent. Karyotype was complex in all cases and monosomal in 90%. Treatment details were available in 29 patients: hypomethylating agent (HMA) alone (<jats:italic>n<\/jats:italic>\u2009=\u20095), HMA\u2009+\u2009venetoclax (<jats:italic>n<\/jats:italic>\u2009=\u200912), intensive chemotherapy (<jats:italic>n<\/jats:italic>\u2009=\u20094), supportive care\/other (<jats:italic>n<\/jats:italic>\u2009=\u20098); no responses or allogeneic stem cell transplants were documented, and all patients died at a median 1.8 months (range 0.2\u20139.3). The current study highlights a consistent and reproducible set of morphologic and genetic characteristics that identify PEL as a distinct AML variant whose dismal prognosis requires urgent attention.<\/jats:p>","DOI":"10.1038\/s41408-022-00746-x","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T07:02:35Z","timestamp":1667372555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-0778","authenticated-orcid":false,"given":"Kaaren K.","family":"Reichard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maymona","family":"Abdelmagid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Alexandres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Haack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia T.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"746_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"746_CR2","unstructured":"Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Foucar K et al. Acute myeloid leukemia and precursor neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon; 2017. pp.129\u201371."},{"key":"746_CR3","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. The International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphological, Clinical, and Genomic Data. In Press; 2022."},{"issue":"Jul","key":"746_CR4","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(Jul):1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1. Epub 2022 Jun 22PMID: 35732831; PMCID: PMC9252913.","journal-title":"Leukemia"},{"key":"746_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01060-8","volume":"23","author":"OK Weinberg","year":"2021","unstructured":"Weinberg OK, Arber DA. Erythroleukemia: an Update. Curr Oncol Rep. 2021;23:69.","journal-title":"Curr Oncol Rep"},{"key":"746_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/MOH.0000000000000314","volume":"24","author":"DA Arber","year":"2017","unstructured":"Arber DA. Revisiting erythroleukemia. Curr Opin Hematol. 2017;24:146\u201351.","journal-title":"Curr Opin Hematol"},{"key":"746_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/modpathol.2017.175","volume":"31","author":"EF Reinig","year":"2018","unstructured":"Reinig EF, Greipp PT, Chiu A, Howard MT, Reichard KK. De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity. Mod Pathol. 2018;31:705\u201317.","journal-title":"Mod Pathol"},{"key":"746_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12308-020-00431-7","volume":"14","author":"C Alexandres","year":"2021","unstructured":"Alexandres C, Basha B, King RL, Howard MT, Reichard KK. p53 immunohistochemistry discriminates between pure erythroid leukemia and reactive erythroid hyperplasia. J Hematopathology. 2021;14:15\u201322.","journal-title":"J Hematopathology"},{"key":"746_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ajcp\/aqaa216","volume":"156","author":"RL King","year":"2020","unstructured":"King RL, Siaghani PJ, Wong K, Edlefsen K, Shane L, Howard MT, et al. Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 translocation in an infant erythroblastic sarcoma. Am J Clin Pathol. 2020;156:129\u201338.","journal-title":"Am J Clin Pathol"},{"key":"746_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.4065\/83.7.776","volume":"83","author":"WG Morice","year":"2008","unstructured":"Morice WG, Kurtin PJ, Hodnefield JM, Shanafelt TD, Hoyer JD, Remstein ED, et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc. 2008;83:776\u201385.","journal-title":"Mayo Clin Proc"},{"key":"746_CR11","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan J, Hastings RJ, Moore S, editors. ISCN 2020: An International System for Human Cytogenomic Nomenclature. Basel: Karger; 2020.","DOI":"10.1159\/isbn.978-3-318-06867-2"},{"key":"746_CR12","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood-2016-11-749903","volume":"129","author":"G Montalban-Bravo","year":"2017","unstructured":"Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, et al. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017;129:2584\u2013258.","journal-title":"Blood"},{"key":"746_CR13","doi-asserted-by":"crossref","unstructured":"Fang H, Wang SA, Khoury JD, El Hussein S, Kim DH, Tashakori M, et al. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases. Haematologica. 2022;107:2232\u20132237.","DOI":"10.3324\/haematol.2021.280487"},{"key":"746_CR14","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia. Haematologica 2022;107:2501\u20135.","journal-title":"Haematologica"},{"key":"746_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41408-020-00388-x","volume":"10","author":"N Gangat","year":"2020","unstructured":"Gangat N, Tefferi A. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. Blood Cancer J. 2020;10:122.","journal-title":"Blood Cancer J"},{"key":"746_CR16","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ajh.25978","volume":"95","author":"E Morsia","year":"2020","unstructured":"Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95:1511\u201321. https:\/\/doi.org\/10.1002\/ajh.25978. Epub 2020 Sep 16.","journal-title":"Am J Hematol"},{"key":"746_CR17","doi-asserted-by":"publisher","first-page":"E232","DOI":"10.1002\/ajh.26546","volume":"97","author":"T Badar","year":"2022","unstructured":"Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, et al. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022;97:E232\u2013E235.","journal-title":"Am J Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00746-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00746-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00746-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T07:06:03Z","timestamp":1667372763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00746-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00746-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We obtained a waiver for informed consent for the study. This study was approved by the Mayo Clinic Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"147"}}